

No Association of Folate- Related and Methionine Synthesis Genes Variant in the Development and Progression of Childhood ALL among North Indian Population

Mohsen Nikbakht,^{1,4} Abhimanyu Kumar Jha,¹ Kianoosh MalekZadeh,² Marjan Askari,¹ Neena Capalash,¹ Marwaha Ram Kumar,³ Deepak Kaul,⁴ Jagdeep Kaur,¹

¹Department. of Biotechnology, Panjab University (PU), Chandigarh, India

²Molecular Medicine Research Center: Medical University of Hormozgan, Bandar Abbas, Iran.

³Advanced Pediatric Center, Post Graduate Institute of Medical Education and Research, Chandigarh (PGIMER), India

⁴Department of experimental medicine and Biotechnology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Corresponding author: Jagdeep Kaur, PhD, Department of Biotechnology, Panjab University, Chandigarh 160014, India, Tel.: 0091-9876187669, Email: jagsekhon@yahoo.com

Abstract

Introduction: Acute Lymphoblastic Leukemia (ALL) is the most worldwide common type of childhood cancer. Methylenetetrahydrofolate reductase (MTHFR) and 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) are crucial enzymes in folate pathways. Folate availability is critical factor for DNA integrity, required for the transfer of methyl group in the biosynthesis of thymidilate.

Procedure: In present study, we have conducted a case control study from north Indian states to correlate the effect of two SNPs of MTHFR (677C→T and 1298A→C) and MTR (2756A→G) and the risk of childhood ALL. One hundred and twenty five bone marrows and peripheral blood samples and 100 sex-age matched healthy controls were obtained and analyzed by PCR-RFLP method.

Results: Statistically, no significant differences were observed between patients and controls for different genotypes ($p>0.05$), also significant different on risk of ALL in individuals having genotype of MTHFR 677TT (OR=0.61, 95% CI=0.21-1.77) and MTHFR 1298CC (OR=0.56, 95% CI=0.18-1.68) was not observed. Statistically, the correlation of variants of MTR gene and risk of ALL was not observed.

Conclusions: The difference in distribution of possible combined genotypes of MTHFR (677C→T, 1298A→C) and MTR (2756A→G) between patients and controls were statistically insignificant.

Keywords: Methylenetetrahydrofolate reductase (MTHFR); 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR); Acute Lymphoblastic Leukemia (ALL); Hypomethylation

Introduction

Acute Lymphoblastic Leukemia (ALL) is a malignant neoplasm of hematopoietic stem cells, which is the most common cancer among children with a peak incidence in 4-5 years of age.(1) It accounts for 23% of childhood cancers (children younger than 15 years).(2) It is still the most common malignant disorder in childhood and principal cause of death due to disease in the pediatric age group, especially prevalent in male.(3) Any deregulation in proliferation on one side or uncontrolled differentiation and apoptosis on other side of progenitor cells pioneer ALL.(4) Interaction of genetic and environmental factors together may enhance the risk of leukemogenesis.(3)

Folate metabolism is playing crucial role for cellular functioning and it serves as donor of one carbon for the synthesis of purines and pyrimidines which are used for the synthesis of RNA and DNA.(3-5-6-7) Normal metabolism of folate might be affected by balance of nutrition, cellular transport interruption and mutation in folate-related genes. Several mutations in folate-related gene sequences have been reported. However, the effect of the most of these mutations on folate related gene still is unclear.(3-4) Deficiency of folate or non-homogenous distribution of folate vitamins may influence the risk of cancer by misincorporation of uracil into DNA and leading to double-strand breaks and chromosomal damage,

DNA hypomethylation/demethylation of some tumor suppressor genes by which it modulate the leukemogenesis.(8-9-10-11) The Methylenetetrahydrofolate reductase (MTHFR) gene is located on chromosome 1p36(12) and translated to enzyme which catalyzes the reduction of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. 5-methyltetrahydrofolate acts as a carbon donor for de novo methionine synthesis and DNA methylation.(13-14-15) MTHFR influences the process of DNA methylation and distribution of uridylates and thymidylates base for DNA synthesis and repair. Therefore it makes the MTHFR and its role in folate pathways as important candidate for study of cancer predisposing gene.(12-15-17) Two frequently reported and well studied mutations in sequence of methylenetetrahydrofolate reductase gene are (MTHFR 677C→T and 1298A→C) which reduces the activity of encoded enzyme.(16-17) The folate used for synthesis of purine and pyrimidine is accumulated in the form of 5-methyltetrahydrofolate (the most abundant form in wild-type MTHFR 677 CC subjects).(18-19) 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) gene is located on 1q43. It is the enzyme which catalyzes the transfer of methyl base from 5-methyl THF to homocysteine.(20) It is reported to have a polymorphism in locus 2756 (A→G i.e glycine→aspartic acid), resulting in reduced enzyme activity and it is considered as a prime cause for elevation of homocysteine and subsequently DNA hypomethylation.(20-21) Several reports have indicated that substitution of C→T at locus 677, A→C at locus 1298 of MTHFR gene and A→G at locus 2567 of MTR gene reduce the enzyme activity and results in hypomethylation of DNA and subsequently reduced incidence of DNA double-strand breakage.(21) Hence, the study of these SNPs can rationally assist to determine the risk of group to ALL and also can be used for study of development and progression of childhood ALL in the population study. The aim of this work is to investigate frequency of MTHFR and MTR polymorphisms and their interaction with respect to possible effect on risk of childhood ALL among North Indian population.

Methods

Specimens: Total 125 bone marrow aspirates were collected from the patient at initial time of diagnosis and prior to any treatment during admission to Hemato-oncology ward (2007-2009), Advanced

Pediatric Center, PGIMER, Chandigarh, India. Informed consent was obtained from all patients in accordance with the institutional guidelines and the declaration of PGIMER. The ethical committees of PGIMER approved the protocol.

Diagnosis was based on morphological, cytogenetic and immunophenotypic criteria of WHO classification(39) by Department of Hematology, PGIMER. The clinical characteristic of the ALL patients have been shown in Table-1.

Control samples were obtained from blood of healthy donor with respect of median and mean of age and sex of patients. The mononuclear cell fraction was separated from bone marrow aspirate and blood by Ficoll density gradient centrifugation (Ficoll Hystopaqu, Sigma Aldrich, USA) and was used for DNA isolation. All samples contained at least 40% blast cells.

DNA isolation: DNA was extracted from mono nuclear cells of bone marrow and blood by standard proteinase K digestion followed by phenol-chloroform method (27).

DNA quantity and quality was determined by spectrophotometry, measuring the optical density at 260 nm and 280 nm of the prepared diluted DNA (1 OD at 260 nm unit =50 µg/mL) and 260nm/280nm.

Detection of MTHFR 677C→T, 1298A→C and MTR 2756 A→G SNPs: Genomic DNA containing the polymorphic sites were amplified by polymerase chain reaction (PCR) with specific primers for each gene (Table- 2) using 15 ng genomic DNA, 0.5 µM of each of the primers, 100 µM deoxyribonucleotide triphosphates (dNTPs), 10 mM Tris (tris-(hydroxymethyl) aminomethane)-HCl (pH 8.3), 1.5 mM MgCl₂, 50 mM KCl, and 0.5 units of Taq polymerase (Sigma–Aldrich, USA) in a total volume of 50 µl.

The PCR conditions were as mentioned in Table-2. RFLP was performed with restriction enzymes according to the manufacturer's instructions (MBI, Fermentas, Burlington, ON, Canada). The restriction digestion was visualized after electrophoresis on 2.5 % agarose gel. The amplified PCR product of MTHFR 677C→T, digested by Hinf restriction enzyme.

Those patients carrying genotype CC showed a single band of 198 bp, whereas carrier of genotype TT showed bands of 175 and 23 bp, and three bands of 198, 175 and 23bp appeared with genotype CT. After digesting with MboII for detecting MTHFR 1298A→C, the bands 56, 31, 30, 28 and 18 bp were observed for genotype AA, whereas, the expected

Table-1. Demography of study.

Variable	Patient	Controls
Gender		
Male	97 (77.6%)	77(77%)
Female	28 (22.4%)	23(23%)
Age		
Mean (±SD)	6.46 (±3.34)	6.55 (±3.37)
Rang	1 - 14	
Age group		
>2 years	12 (9.6%)	11 (11%)
2-5 years	43 (34.4%)	33 (33%)
5>years	70 (56%)	56 (56%)
NCI Risk group		
Standard	103(82.4)	-
High	22(17.6)	-

Table- 2. Primer sequences and PCR Conditions.

Gene	Primer Sequence (5'- 3')	Annealing temp. (°C)/time/cycle
MTHFR677		
F	TGA AGG AGA AGG TGT CTG CGG GA	59/1 min/35
R	AGG ACG GTG CGG TGA GAG TG	
MTHFR1298		
F	CTT TGG GGA GCT GAA GGA CTA CTA C	59/1 min/35
R	CAC TTT GTG ACC ATT CCG GTT TG	
MTR2756		
F	TGT TCC AGA CAG TTA GAT GAA AAT C	60/1 min/35
R	GAT CCA AAG CCT TTT ACA CTC CTC	

Table- 3. Frequencies of MTHFR 677C→T, 1298A→C and MTR 2756A→G genotypes in case and control.

Genotype	Case	Control	OR	CI(95%)	P-Value
MTHFR C677T					
CC	54(43.2%)	40(40%)	1		
CT	62(49.6%)	49(49%)	0.94	0.52-1.69	0.93
TT	9(7.2%)	11(11%)	0.61	0.21-1.77	0.3
CT+TT	71(56.8%)	60(60%)	0.88	0.50-1.55	0.72
MTHFR A1268C					
AA	52(41.6%)	40(40%)	1		
AC	65(52%)	49(49%)	1.02	0.56-1.85	0.94
CC	8(6.4%)	11(11%)	0.56	0.18-1.68	0.37
AC+CC	73(58.4%)	60(60%)	0.94	0.53-1.66	0.91
MTR A2756G					
AA	74(59.2%)	58(58%)	1		
AG	44(35.2%)	35(35%)	0.99	0.54-1.80	0.92
GG	7(5.6%)	7(7%)	0.78	0.23-2.66	0.87
AG+GG	51(40.8%)	42(42%)	0.95	0.54-1.68	0.96

Table- 4. Interaction of MTHFR genotypes between case and control.

Combined genotypes	Cases(125)	Controls(100)	OR	CI (95%)	P-Value
677CC/1298AA	22(17.6%)	16(16%)	-	-	-
677CT/1298AA	40(32%)	20(20%)	0.52	0.1-1.54	0.18
677TT/1298AA	8(17.6%)	12(12%)	1.35	0.34-5.47	0.63
677CC/1298AC	20(6.4%)	22(22%)	0.51	0.17-1.48	0.16
677CT/1298AC	17(13.6%)	18(18%)	0.49	0.16-1.5	0.16
677TT/1298AC	0(0%)	0(0%)	NA	NA	NA
677CC/1298CC	13(10.4%)	12(12%)	0.73	0.2-2.55	0.57
677CT/1298CC	5(4%)	7(7%)	0.72	0.35-1.48	0.51
677TT/1298CC	0(0%)	0(0%)	NA	NA	NA

bands for genotype CC were 84, 31, 30 and 18 bp and for heterozygous (AC), the size of expected bands were 84, 56, 31, 30, 28 and 18 bp. The amplified product of MTR 2756A→G gene followed by digestion by HaeIII, the carrier of

genotype AA showed the single band at 211 bp. Those homozygous for mutation (GG) showed bands of 131 and 80bp. Heterozygous (AG) represented bands of 211, 131 and 80 bp.

Table- 5. Frequencies of combined genotype in childhood ALL and control.

Combined genotypes	Cases	Controls	OR	CI(95%)	P-Value
CCAAAA	14	7	Ref.	-	-
CCAAAG	6	5	0.82	0.44-1.52	0.70
CCAAGG	5	4	0.83	0.43-1.61	0.68
CCACAA	15	8	0.98	0.64-1.50	0.82
CCACAG	12	7	0.86	0.19-3.81	0.92
CCACGG	0	0	NA	NA	NA
CCCCAA	2	2	0.75	0.27-2.09	0.60
CCCCAG	2	1	1	0.43-2.35	1
CTAAAA	18	9	1	0.25-3.97	1
CTAAAG	8	1	1.33	0.91-1.95	0.37
CTAAGG	2	1	1	0.43-2.35	1
CTACAA	15	10	1.33	0.34-5.32	0.64
CTACAG	13	5	0.77	0.16-3.71	0.7
TTAAAA	1	1			

Table- 6. Frequencies of variants in male and female.

Genotype	Male					Female				
	Case 97(%)	Control 77(%)	OR	CI (95%)	P-Value	Case 28 (%)	Control 23 (%)	OR	CI (95%)	P-Value
MTHFR C677T										
CC	44(45.3)	29(37.6)	Ref.	-	-	10(35.7)	11(47.8)	Ref.	-	-
CT	47(48.4)	39(50.6)	0.79	0.4-1.54	0.58	15(53.5)	10(43.4)	1.24	0.72-2.19	0.58
TT	6(6.1)	9(11.6)	0.66	0.35-1.27	0.24	3(10.7)	2(8.6)	1.26	0.54-2.93	1
CT+TT	52(53.6)	56(72.7)	0.80	0.61-1.05	0.14	18(64.2)	12(52.1)	1.26	0.74-2.15	0.55
MTHFR A1268C										
AA	38(39.1)	30(38.9)	Ref.	-	-	14(50)	11(47.8)	Ref.	-	-
AC	53(54.6)	41(53.2)	1.02	0.52-2.01	0.92	12(42.8)	9(39.1)	1.02	0.61-1.67	0.82
CC	6(6.1)	6((7.7)	0.79	0.2-3.14	0.94	2(7.1)	3(13)	0.71	0.23-2.21	0.64
AC+CC	59(60.8)	47(61)	0.99	0.51-1.92	0.89	14(50)	12(52.1)	0.92	0.26-3.19	0.89
MTR A2756G										
AA	56(57.7)	45(58.4)	Ref.	-	-	17(60.7)	14(60.8)	Ref.	-	-
AG	33(34)	25(32.4)	1.06	0.53-2.14	0.99	8(28.5)	6(26)	1.10	0.26-2.16	0.85
GG	8(8.2)	7(9)	0.92	0.28-3.09	0.90	3(10.7)	3(13)	0.91	0.39-2.16	1
AG+GG	38(39.1)	31(40.2)	0.99	0.51-1.91	0.91	11(39.2)	9(39.1)	1.01	0.28-3.62	0.78

Table-7. Frequencies of genotypes in standard and high risk group patients.

Genotype	Standard Risk Group 103(%)	High Risk Group 22(%)	OR	CI (95%)	P-Value
MTHFR C677T					
CC	45(43.7)	11(50)	Ref.	-	-
CT	51(49.5)	9(40.9)	1.39	0.48-4.05	0.67
TT	7(6.7)	2(9)	0.97	0.67-1.04	1
CT+TT	58(56.3)	11(50)	1.29	0.47-3.65	0.76
MTHFR A1268C					
AA	43(41.7)	9(41)	Ref.	-	-
AC	53(51.4)	11(50)	1.01	0.34-2.93	0.81
CC	7(6.7)	1(4.5)	1.06	0.79-1.41	1
AC+CC	60(58.2)	12(54.5)	1.05	0.37-2.97	0.88
MTR A2756G					
AA	60(58.2)	14(63.6)	Ref.	-	-
AG	38(36.9)	7(31.8)	1.27	0.43-3.85	0.82
GG	5(4.8)	1(4.5)	1.03	0.71-1.49	1
AG+GG	43(41.7)	8(36.3)	1.25	0.44-3.62	0.82

Table- 8. Frequencies of genotypes in different age group.

Genotype	Age<2					2≤Age<5					Age>5				
	Case 12(%)	Control 11(%)	OR	CI (95%)	P-Value	Case 45(%)	Control 32(%)	OR	CI(95%)	P-Value	Case 68(%)	Control 57(%)	OR	CI (95%)	P-Value
MTHFR C677T															
CC	6(50)	4(36.3)	-	-	-	19(42.2)	14(43.7)	-	-	-	29(42.6)	22(38.5)	-	-	-
CT	5(41.6)	6(54.5)	0.76	0.33-1.72	0.6	23(51.1)	16(50)	1.06	0.37-1.52	0.9	34(50)	25(43.8)	1.03	0.45-2.36	0.91
TT	1(8.3)	1(9)	0.83	0.19-3.64	1	3(6.6)	4(12.5)	0.74	0.3-1.84	0.67	5(7.3)	7(12.2)	0.73	0.36-1.49	0.52
CT+TT	6(50)	7(63.6)	0.77	0.34-1.67	0.68	26(57.7)	20(62.5)	0.96	0.35-2.6	0.89	39(57.3)	32(56.1)	0.95	0.43-2.11	0.95
MTHFR A1268C															
AA	5(41.6)	4(36.3)	-	-	-	17(37.7)	12(37.5)	-	-	-	30(44.1)	24(42.1)	-	-	-
AC	7(58.3)	5(45.4)	1.05	0.49-2.23	1	24(53.3)	17(53.1)	1	0.34-2.29	0.81	34(50)	27(47.3)	1.01	0.45-2.25	0.86
CC	1(8.3)	1(9)	0.90	0.20-4.05	1	3(6.6)	3(9.3)	0.85	0.36-2.01	1	4(5.8)	7(12.2)	0.65	0.29-1.48	0.40
AC+CC	8(66.6)	6(54.5)	1.03	0.49-2.16	1	27(60)	20(62.5)	0.95	0.34-2.70	0.88	38(55.8)	34(59.6)	0.89	0.41-1.93	0.89
MTR A2756G															
AA	7(58.3)	6(54.5)	-	-	-	28(62.2)	20(62.5)	-	-	-	39(57.3)	32(56.1)	-	-	-
AG	4(33.3)	4(36.3)	0.93	0.39-2.19	1	16(35.5)	11(34.3)	1.04	0.36-3.02	0.86	24(35.2)	19(33.3)	1.02	0.72-1.43	0.91
GG	0(0)	0(0)	-	-	-	2(4.4)	2(6.2)	0.86	0.31-2.35	1	5(7.3)	5(8.7)	0.91	0.47-1.75	1
AG+GG	4(33.3)	4(36.3)	0.93	0.39-2.19	1	18(40)	13(40.6)	1	0.68-1.46	0.83	29(42.6)	24(42.1)	0.99	0.46-2.16	0.87

Statistical analysis: Distribution of MTHFR 677C→T and MTHFR 1298A→C and MTR 2756A→G variant among patients and controls were tabulated for cases and controls (Table- 3). With respect to assumption which indicates that MTHFR and MTR genotypes may be associated with the risk of ALL, we tested genotypes interaction in models for acute lymphoblastic leukemia and the interaction of these genes with age, sex and hematological classification, risk group. The χ^2 test was used to examine differences in frequencies between MTHFR 677C→T, MTHFR 1298A→C and MTR 2756A→G genotypes in cases and controls. Fisher exact test was used when cell numbers were less than 5. The relationship between MTHFR and MTR genotypes and risk of ALL was assessed by means of the odds ratio (OR) with 95% confidence interval (95%CI). It was calculated using both conditional and unconditional logistic regression (adjusting for age and sex) by use of software version 11.5 (SPSSs, Chicago, IC), and EPI software version 3.2.

Result

Demographic data of cases and controls has been summarized in Table-1. The variables have also been categorized for ALL immunophenotypes. The blast lineage, NCI risk groups of ALL patients have been tabulated in Table- 1. 94.4% patients were diagnosed with B-lineage ALL and 5.6% with T-lineage ALL. The distribution of ALL patients on the basis of NCI risk groups were 82.4% in standard risk group and 17.6% in high risk group.

The mean age (\pm SD) of all cases and controls were 6.46 (\pm 3.34) and 6.55 (\pm 3.37) years ($p=0.245$) respectively. Around 9.6 % of patients were in the age-group of age ≤ 2 years and 34.4 % were in the age-group of $2 < \text{age} \leq 5$ and 56% were in age of more than 5 years, whereas it was 11%, 33% and 56% respectively for healthy controls. The number of males and females among cases and controls were almost similar (77.6: 77 for males and 22.4: 23 for females, respectively). The distribution pattern of ALL patients and controls according to place of living were divided in to two groups (a) urban (b) rural. 35.2% of patients were living in urban and 64.8% were living in rural areas. The values for controls were not different from cases (38% urban and 62% rural). The distribution of ALL cases and controls among different states of North India showed the most of the patients in present study were from Punjab (44%), followed by Haryana (27.2%), Uttar Pradesh (12.8%), Himachal Pradesh

(8%), Chandigarh (4.0%) and J&K (4%). Similar distribution was seen among the controls.

The frequencies of genotypes of MTHFR and MTR genes in patients and controls were depicted in Table III. The frequencies of MTHFR C677T/A1298C, MTR A2756G variants in childhood ALL and healthy controls did not deviate significantly from the Hardy–Weinberg equilibrium.

The prevalence of genotypes 677CC, 677CT and 677TT was 43.2%, 49.6% and 7.2% for patients, respectively, whereas it was 40%, 49%, and 11% in controls (frequency of mutated-allele T was 40% of patients and 35.5% of controls). The distribution of AA, AC and CC genotype in MTHFR 1298A→C, was 41.6%, 52% and 6.4% of patients and 40%, 49% and 11% for controls, respectively. The frequency of mutated-allele (C) was 40.5% for patients and 35.5% for controls. The prevalence of genotypes 2756AA, 2756AG and 2756GG was 59.2%, 35.2% and 5.6% for patients and 52%, 35% and 7% for controls. Twenty nine percent of patients and 24.5% of controls carried at least one mutated-allele of G. No significant difference ($p > 0.05$) was observed between patients and controls in all these studied genes.

The frequencies of MTHFR 677C→T, MTHFR 1298A→C and MTR 2756A→G in stratified risk group is shown in table VII. Significant difference of distribution of genotypes between standard and high risk group was not observed.

The comparison of the frequency distribution of MTHFR 677C→T, MTHFR 1298A→C and MTR 2756A→G polymorphisms between case and control on the bases of sex showed that the distribution of MTHFR 677 and MTHFR 1298 and MTR2756 variants among the both sex were not significantly different ($p > 0.05$) (Table- 6). Also on the basis of age-group (the age of the children at the time of diagnosis), distribution of genotypes of MTHFR 677C→T, MTHFR 1298A→C and MTR 2756A→G were calculated. However, no significant difference was detected (Table- 8).

The effect of gene-gene interaction between MTHFR polymorphisms on susceptibility of childhood ALL was investigated further; significant association between the interaction of MTHFR variants and development and progression of ALL among the children in the present study was on observed (Table- 4).

As it is shown in Table- 3, individuals who carried the genotype of MTHFR 677TT, did not show and difference on risk of ALL (OR=0.61; 95%CI=0.21-1.77). The adjusted OR for carriers of MTHFR

1298CC genotype was calculated. It was 0.56 (95%CI=0.18-1.68) which statistically did not show significance reduction on susceptibility against of childhood ALL. Moreover, this trace was not observed for variants of 2756A→G gene.

The significance was not altered when these 3 polymorphisms were evaluated in combination (Table- 5).

Discussion

Polymorphism of genes which regulate the metabolism of folate is the important phenomenon which may play role in cancer susceptibility by decreasing folate status or by interference in distribution of folate in cells could influence the risk of ALL.(22) Childhood ALL is more prone to environmental exposures during fetal and infant stage.(10) Different folate metabolism pathways, it reduced the level of 5, 10-methylene-THF (MTHFR Substrate) which is essential for synthesis of thymidylate consequently lead to uracil misincorporation into DNA. It further inhibited the DNA repair system and increased the susceptibility to double-strand breakage there by leading to the chromosomal damage and translocation.(23- 26) Folate availability is critical for DNA integrity, required for the transfer of methyl groups in the biosynthesis of thymidilate.

The decrease in activity of MTHFR could affect the nucleotide synthesis by increasing availability of the 5, 10-methylene-THF which is required for DNA synthesis and cell division. Folate distribution decreases the transmethylation capacity and thereby decreasing S-adenosylmethionine/S-adenosylhomocysteine ratio and methylation of homocysteine to methionine. Diminished folate availability, increases the probability of misincorporation of uracil in DNA strand at the time of replication and subsequently increasing the frequency of chromosomal breakage in human leukocyte.

A hematological malignancy like ALL is more vulnerable to DNA and chromosomal damage because, folate deficiency in them can not accomplish the demand of hasty DNA synthesis in uncontrolled and rapidly proliferating hematopoietic cells. DNA hypomethylation and uracil misincorporation are considered important factors in carcinogenesis.(27- 11)

Several groups have reported that, the polymorphisms which reduce the MTHFR activity were associated with the reduced risk of leukemia and lymphoma.(10- 28- 41) ALL patients with polymorphisms in serine hydroxymethyl transferase

gene and thymidylate synthase genes are considered as low risk group.(15- 29) ALL cases with a polymorphisms in MTR 2756A→G genotype) showed reduction by 5.6-fold in adult ALL risk.(29) Not only MTR 2756A→G variants were considered as a risk allele for ALL but also in combination with the MTHFR variants.(14)

In this study, attempts were made to evaluate the associations between the MTHFR 677C→T, MTHFR 1298A→C and MTR 2756A→G polymorphisms and the risk of ALL in the 125 cases of the Childhood ALL in north India compared with the sex and age matched controls. It has been reported that both MTHFR polymorphisms reduce the susceptibility to adult and childhood lymphoid leukemia however not in myeloid leukemia.(30-10-31-32-33-41-42)

The significant protective effect of MTHFR 677C→T variant but not MTHFR 1298A→C in the Brazilian population to decrease the risk of childhood ALL has been reported by de Franchis et al.(13) Recently Sood et al., 2010 demonstrated the significant protective effect of MTHFR 677C→T variant but not MTHFR 1298A→C in the north Indian population to decrease the risk of childhood ALL .Wiemels et al., reported the protective effect of MTHFR 677C→T polymorphism on the risk for infant leukemia in the UK population but not for MTHFR 1298A→C polymorphism also they demonstrated 677C/T frequency was higher in ALL patients with MLL rearrangements, low in ALL with hyper-diploidy which indicating that impact of 677C/T variant on development and progression of leukemia might vary between different subtype of ALL.(33) Matsuo et al., provided the evidence which MTHFR mutant alleles are associated with lower susceptibility to ALL.(21) Some other studies also reconfirmed that both MTHFR polymorphisms decreased the risk for childhood ALL in French-Canadian population.(5) The recent report by Reddy et al., suggested a possible protective effect of MTHFR (677C→T) and MTHFR 1298A→C) for the first time they reported gender-bias protective effect of 677CT /1298AA and 677CT/1298AC toward of female ALL patients.(34) Yeoh et al., demonstrated association between MTHFR 1298A→C and increasing the risk of ALL among male patients.(38)

However, other research groups reported no association between MTHFR polymorphisms and the risk for childhood ALL, from different ethnic groups.(13-15-21) Wang et al., 2010 in their recent meta- analysis reported albeit MTHFR C677T was found previously to be associated with increased

risks of colorectal cancer, leukemia, and gastric cancer, but on the bases of this Meta –analysis they could not find evidence for a main role of MTHFR C677T in the leukemogenesis of childhood acute lymphoblastic leukemia.

In the present study, significant difference between patients and healthy controls was not observed, but also our result did not show the significant reduction in the risk of ALL and increasing the tolerance induced by T and C alleles in position of 677 and 1298 of MTHFR gene, respectively, in ALL patients in north Indian population.

In this study we tried to find out whether MTHFR variants and MTR polymorphism play a protective role in a childhood ALL.

We tried to analyzing the influence of each polymorphism of MTHFR and MTR individually and in combination and their effect on the risk for childhood ALL. We could not observe significant associations between the genetic polymorphisms of the folate metabolizing enzymes and MTR on the risk for childhood ALL in our population of study.

However, the contradictory results were observed in association of genetic polymorphisms in the folate metabolic pathway with the risk for adult ALL.(29-28-30-36-38) Also, Gemmati et al., and Lincz et al., observed that MTR 2756A→G polymorphism reduced the risk for adult ALL and lymphoma. On the other hand, Skibola et al., and Matsuo et al., reported an increased risk for different types of adult lymphoma in carriers for at least one G allele in locus 2756 of MTR gene. Our work showed no association between MTR 2756A→G polymorphism and the risk for adult ALL, which also reported by Skibola et al., and Kamel et al.,(29-36) the inconsistencies of results might be attributed to some variables in study of population like size of sampling, age and nutritional folic acid in diet. Rosenberg et al, showed that the adequate folic acid consumption in a population may increase the frequency of the MTHFR 677T allele, in contrast insufficient level of folate in diet may results in decreasing the T allele frequency. This can justify the different frequency of MTHFR allele in population of this study as compared with Ready et al may influenced by different level of folic acid in diet of different ethnic groups in India. Thus the polymorphism of these genes did not show any effect on ALL susceptibility, could be interpreted that other molecular mechanisms like hypermethylation mediated gene silencing may play an important role in etiology of ALL in north Indian population.

The mechanism proposed to explain these associations was the deviation of folate metabolism versus thymidine and purine synthesis, which would, reduces the possibility of the incorporation of uracil into DNA and protect against carcinogenesis. It has been proposed that shunt of folate metabolism encounters the synthesis of thymidine and purine, reduces misincorporation of uracil into DNA and protect from any damage which lead to arising cancer.(10-34)

In conclusion, the present study provided the evidence that MTHFR (677 C→T), MTHFR (1298 A→C) and MTR (2576A→C) are not associated with decreased risk of childhood ALL and did not show significant effect on progression and development of childhood ALL, MTR (2576A→C), which suggested that folate and methionine metabolism pathway genes might have an important protective role. But in population of study these polymorphisms did not show significant effect on development and progression of childhood ALL.

According to this study, MTHFR 677C→T and 1298A→C may could not be considered as a crucial and probable marker for development and progression and also could not be used for treatment strategies for childhood ALL, as epigenetic mechanisms are more important in progression of childhood ALL. The larger studies, which in turn will be able to provide support to truly significant finding through much larger combined and comparative data sets, are necessary in this regard.

Acknowledgement

We are indebted to all patients and their parents who consented to participate in this study. This work was supported by University Grand Commission (UGC) India.

References

1. Pui CH, Relling MV, Downing JR. Acute Lymphoblastic Leukemia. *N Engl J Med* 2004;350:1535– 48.
2. Lichtman, Marshall; Beutler, Ernest; Kaushansky, Kenneth; Kipps, Thomas; Seligsohn, Uri; Prchal, Josef William's Hematology McGraw-Hill Edition: 7th Year: 2005 ISBN-10: 0071435913.
3. Sinnott D, Krajcinovic M, Labuda D. Genetic Susceptibility to Childhood Acute Lymphoblastic Leukemia. *Leuk Lymphoma*. 2000; 38: 447- 462.
4. Young-In Kim: Methylenetetrahydrofolate Reductase Polymorphisms, Folate, and Cancer Risk: A Paradigm of Gene-Nutrient Interactions in Carcinogenesis *Nutrition Reviews* 2009; 58(7): 205– 209.

5. Wagner C. Biochemical Role of Folate in Cellular Metabolism. Bailey L.B. eds. Folate in Health and Disease 1995:23-42 Marcel Dekker New York, NY.
6. Miller JW, Nadeau MR, Smith J, Smith D, Selhub J. Folate Deficiency-induced Homocysteinemia in Rats: Disruption of Sadenosylmethionine Coordinate Regulation of Homocysteine Metabolism. *Biochem J* 1994;298:415-9.
7. Ryan, B. M. & Weir, D. G. (2001) Relevance of Folate Metabolism in the Pathogenesis of Colorectal Cancer. *J. Lab. Clin. Med.* 138: 164-176.
17. Jones, P. & Laird, P. Cancer Epigenetics Comes of Age. *Nat. Genet.* 1999; 21: 163-167.
8. Duthie SJ, Narayanan S, Brand GM, Pirie L, Grant G. Impact of Folate Deficiency on DNA Stability. *J Nutr.* 2002;132[*suppl*]:2444- 2449.
9. Lucock M. Is Folic Acid the Ultimate Functional Food Component for Disease Prevention? *BMJ.* 2004; 328:211-214.
10. Skibola CF, Smith MT, Kane L, et al. Polymorphisms in the Methylene-tetrahydrofolate Reductase Gene are Associated with Susceptibility to Acute Leukemia in Adults. *Proc Natl Acad Sci U S A.* 1999;96:12810-12815.
11. Dianov GL, Timchenko TV, Sinitsina OI, et al. Repair of Uracil Residues Closely Spaced on the Opposite Strands of Plasmid DNA Results in Double-Strand Break and Deletion Formation. *Mol Gen Genet* 1991;225:448- 52.
12. Goyette P, Summers JS, Milos R, et al. Human Methylene-tetrahydrofolate Reductase: Isolation of cDNA Mapping and Mutation Identification. *Nat Genet.* 1994;7: 195-200.
13. de Franchis R, Sebastio G, Mandato C, Andria G, Mastroiacovo P. Spina Bifida. 677T-->C Mutation, and Role of Folate. *Lancet* 1995; 346: 1703.
14. Frosst P, Blom HJ, Milos R, et al. A Candidate Genetic Risk Factor for Vascular Disease: A Common Mutation in Methylene-tetrahydrofolate Reductase. *Nat Genet* 1995; 10: 111-113.
15. Botto N, Andreassi MG, Manfredi S, et al. Genetic Polymorphisms in Folate and Homocysteine Metabolism as Risk Factors for DNA Damage. *Eur J Hum Genet* 2003; 11: 671-678.
16. Lightfoot TJ, Skibola CF, Willett EV, et al: Risk of non-Hodgkin Lymphoma Associated with Polymorphisms in Folate-metabolizing Genes. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 2999-3003.
17. van der Put NMJ, Gabreels F, Stevens EMB, et al. A Second Common Mutation in the Methylene-tetrahydrofolate Reductase Gene: an Additional Risk Factor for Neural-tube Defects? *Am J Hum Genet.* 1998; 26: 1044- 1051.
18. Bagley PJ, Selhub J. A Common Mutation in the Methylene-tetrahydrofolate Reductase Gene is Associated with an Accumulation of Formylated Tetrahydrofolates in Red Blood Cells. *Proc Natl Acad Sci U S A.* 1998; 95: 13217- 13220.
19. Etienne MC, Ilc K, Formento JL, Laurent-Puig P, et al. Thymidylate Synthase and Methylene-tetrahydrofolate Reductase Gene Polymorphisms: Relationships with 5-fluorouracil Sensitivity. *Br J Cancer.* 2004; 90: 526-534.
20. Leclerc D, Campeau E, Goyette P, et al. Human Methionine Synthase: cDNA Cloning and Identification of Mutations in Patients of the cbIG Complementation Group of Folate/Cobalamin Disorders. *Hum Mol Genet.* 1996; 5: 1867- 1874.
21. Matsuo K, Suzuki R, Hamajima N, et al. Association Between Polymorphisms of Folate and Methionine-metabolizing Enzymes and Susceptibility to Malignant Lymphoma. *Blood* 2001; 97: 3205- 3209.
22. Kim YI. Folate and Carcinogenesis: Evidence, Mechanisms, and Implications. *J Nutr Biochem.* 1999; 10: 66- 88.
23. Giovannucci E. Epidemiologic Studies of Folate and Colorectal Neoplasia: a Review *J. Nutr.*, August 1, 2002; 132(8): 2350S- 2355.
24. Kim YI. Folate and Cancer Prevention: A New Medical Application of Folate beyond Hyperhomocysteinemia and Neural Tube Defects. *Nutr Rev.* 1999; 57: 314- 321.
25. Ma J, Stampfer MJ, Giovannucci E, et al. Methyl-ene-tetrahydrofolate Reductase Polymorphism, Dietary Interactions, and Risk of Colorectal Cancer. *Cancer Res.* 1997; 57: 1098- 1102.
26. Pogribny IP, Muskhelishvili L, Miller BJ, James SJ. Presence and Consequence of Uracil in Preneoplastic DNA from Folate/Methyl deficient Rats. *Carcinogenesis.* 1997; 18: 2071- 207.
27. Blount BC, Mack MM, Wehr CM, et al. Folate Deficiency Causes Uracil Misincorporation into Human DNA and Chromosome Breakage: Implications for Cancer and Neuronal Damage. *Proc Natl Acad Sci U S A* 1997; 94: 3290- 5.
28. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF. Methylene-tetrahydrofolate Reductase (MTHFR) Polymorphisms and Risk of Molecularly Defined

Subtypes of Childhood Acute Leukemia. *Proc Natl Acad Sci U S A*. 2001; 98: 4004- 4009.

29. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR et al. Polymorphisms in the Thymidylate Synthase and Serine Hydroxymethyltransferase Genes and Risk of Adult Acute Lymphocytic Leukemia. *Blood* 2002; 99:3786- 3791.

30. Gemmati D, Ongaro A, Scapoli GL, et al. Common Gene Polymorphisms in the Metabolic Folate and Methylation Pathway and the Risk of Acute Lymphoblastic Leukemia and non-Hodgkin's Lymphoma in Adults. *Cancer Epidemiol Biomarkers Prev*. 2004; 13: 787-794.

31. Chen J, Giovannucci E, Kelsey K, et al. A Methylenetetrahydrofolate Reductase Polymorphism and the Risk of Colorectal Cancer. *Cancer Res* 1996; 56: 4862- 4.

32. H Nu"ckel, UH Frey, J Du"rig, U Du"hrsenl and W; Siffert: Methylenetetrahydrofolate Reductase (MTHFR) Gene 677C>T and 1298A>C Polymorphisms are Associated with Differential Apoptosis of Leukemic B Cells in vitro and Disease Progression in Chronic Lymphocytic Leukemia: *Leukemia* 2004; 18: 1816- 1823.

33. Krajinovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, Theoret Y, Sinnott D. Role of MTHFR Genetic Polymorphisms in the Susceptibility to Childhood Acute Lymphoblastic Leukemia. *Blood* 2003; 103: 252- 257.

34. Reddy H, Jamil K. Polymorphisms in the MTHFR Gene and their Possible Association with Susceptibility to Childhood Acute Lymphocytic Leukemia in an Indian Population. *Leuk Lymphoma*. 2006; 47(7): 1333- 9.

35. Skibola CF, Forrest MS, Coppede F, et al. Polymorphisms and Haplotypes in Folate-metabolizing Genes and Risk of non-Hodgkin Lymphoma. *Blood* 2004; 104: 2155- 2162.

36. Kamel AM, Moussa HS, Ebid GT, Bu RR, Bhatia KG, Synergistic Effect of Methylenetetrahydrofolate Reductase (MTHFR, C677T and A1298C Polymorphism as Risk Modifiers of Pediatric) Acute Lymphoblastic Leukemia *Journal of the Egyptian Nat. Cancer Inst.*, 2007; 19(2) : 96- 105.

37. Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A. Methionine Synthase Genetic Polymorphism MS A2756G Alters Susceptibility to Follicular but not Diffuse Large B-cell non-Hodgkin's Lymphoma or Multiple Myeloma. *Br J Haematol* 2003; 120: 1051- 1054.

38. Yeoh AE, Lu Y, Chan JY, Chan YH, Ariffin H, Kham SK, Quah TC. Genetic Susceptibility to Childhood Acute Lymphoblastic Leukemia Shows Protection in Malay Boys: Results from the Malaysia-Singapore ALL Study Group. *Leuk Res* 2010; 34: 276- 83.

39. Jaffe E, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.

40. Wang J. et al. MTHFR C677T Polymorphisms and Childhood Acute Lymphoblastic Leukemia: a Meta-analysis. *Leukemia Research*, 2010.

41. Sood S. et al. Methylenetetrahydrofolate Reductase Gene Polymorphisms: Association with Risk for Pediatric Acute Lymphoblastic Leukemia in North Indians. *Leukemia and Lymphoma*, 2010; 51(5): 928- 32.

42. de Jonge R, Tissing WJ, Hooijberg JH, Jansen G, Kaspers GJ, Lindemans J, Peters GJ, Pieters R. Polymorphisms in Folate-related Genes and Risk of Pediatric Acute Lymphoblastic Leukemia. *Blood*. 2009; 113 (10): 2284- 9.

43. Karathanasis NV, Choumerianou DM, Kalmanti M. Gene Polymorphisms in Childhood ALL. *Pediatr Blood Cancer* 2009; 3: 318- 323.